Lindbrook Capital LLC Has $26,000 Stock Position in Bruker Co. (NASDAQ:BRKR)

Lindbrook Capital LLC grew its position in Bruker Co. (NASDAQ:BRKR) by 68.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 360 shares of the medical research company’s stock after buying an additional 146 shares during the quarter. Lindbrook Capital LLC’s holdings in Bruker were worth $26,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Baker Tilly Wealth Management LLC boosted its holdings in shares of Bruker by 3.0% in the fourth quarter. Baker Tilly Wealth Management LLC now owns 5,285 shares of the medical research company’s stock worth $388,000 after buying an additional 156 shares during the period. Legacy Wealth Asset Management LLC boosted its holdings in shares of Bruker by 5.7% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 3,412 shares of the medical research company’s stock worth $251,000 after buying an additional 184 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Bruker by 53.3% in the third quarter. Fifth Third Bancorp now owns 541 shares of the medical research company’s stock worth $34,000 after buying an additional 188 shares during the period. Treasurer of the State of North Carolina boosted its holdings in shares of Bruker by 0.5% in the third quarter. Treasurer of the State of North Carolina now owns 48,140 shares of the medical research company’s stock worth $2,999,000 after buying an additional 235 shares during the period. Finally, Blue Trust Inc. boosted its holdings in shares of Bruker by 14.1% in the fourth quarter. Blue Trust Inc. now owns 1,914 shares of the medical research company’s stock worth $141,000 after buying an additional 237 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bruker

In other news, Director Hermann Fritz Requardt sold 15,000 shares of Bruker stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $90.06, for a total value of $1,350,900.00. Following the transaction, the director now owns 23,147 shares of the company’s stock, valued at $2,084,618.82. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 28.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. JPMorgan Chase & Co. upgraded shares of Bruker from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $60.00 to $90.00 in a report on Wednesday, February 14th. Stifel Nicolaus increased their price target on shares of Bruker from $63.00 to $81.00 and gave the stock a “hold” rating in a research report on Wednesday, February 14th. The Goldman Sachs Group increased their price target on shares of Bruker from $66.00 to $74.00 and gave the stock a “sell” rating in a research report on Wednesday, April 10th. UBS Group increased their price target on shares of Bruker from $94.00 to $102.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Citigroup increased their price target on shares of Bruker from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $84.86.

Bruker Price Performance

Shares of BRKR opened at $80.97 on Friday. The firm has a market cap of $11.77 billion, a PE ratio of 27.73, a PEG ratio of 2.08 and a beta of 1.17. The firm’s 50 day moving average price is $88.10 and its 200 day moving average price is $74.49. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.99 and a current ratio of 1.80. Bruker Co. has a twelve month low of $53.79 and a twelve month high of $94.86.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, February 13th. The medical research company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. The firm had revenue of $844.50 million for the quarter, compared to analyst estimates of $809.35 million. Bruker had a net margin of 14.41% and a return on equity of 29.94%. The company’s revenue for the quarter was up 19.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.74 earnings per share. As a group, research analysts expect that Bruker Co. will post 2.74 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Friday, March 1st were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.25%. The ex-dividend date was Thursday, February 29th. Bruker’s payout ratio is presently 6.85%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.